A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06531824

Title field or adapter rule

{'original_value': 'A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-29T01:00:17.833486+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-10-29T01:00:17.096649+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Kidney Disease, Chronic"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06531824"

protocolSection.identificationModule.officialTitle

"A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Kidney Disease, Chronic (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Part 2: Randomized treatment, follow-up period, treatment group'], 'description': 'BI 690517 (called Type M randomized treatment)', 'name': 'BI 690517', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 2: Follow-up period, placebo group'], 'description': 'Placebo matching BI 690517', 'name': 'Placebo matching BI 690517', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 1: Run-in period (all participants)', 'Part 2: Follow-up period, placebo group', 'Part 2: Randomized treatment, follow-up period, treatment group'], 'description': 'Empagliflozin (called Type E)', 'name': 'Empagliflozin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• BI 690517 (protocolSection.armsInterventionsModule.interventions[].name)
• Placebo matching BI 690517 (protocolSection.armsInterventionsModule.interventions[].name)
• Empagliflozin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.